Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
07. Mai 2024 07:05 ET
|
Apellis Pharmaceuticals, Inc.
Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) ...
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
06. Mai 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Bank of America Securities Healthcare...
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
01. Mai 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that 14 abstracts, 11 of which are oral presentations, will be presented at the...
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
26. April 2024 07:15 ET
|
Apellis Pharmaceuticals, Inc.
Decision by EMA follows recent judgment by the Court of Justice of the European Union regarding the organization of EMA’s expert groupsApellis anticipates a CHMP opinion no later than July 2024 ...
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
23. April 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. April 2024 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant...
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
01. April 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the 23rd Annual Needham Virtual...
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
11. März 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06. März 2024 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
27. Februar 2024 07:05 ET
|
Apellis Pharmaceuticals, Inc.
Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan)Strong SYFOVRE launch, with more than...